Provention Bio Gets FDA OK for Diabetes Drug
18 Novembre 2022 - 12:39AM
Dow Jones News
By Josh Beckerman
Provention Bio Inc. said the U.S. Food and Drug Administration
approved the Biologics License Application for TZIELD as a
treatment to delay the onset of Stage 3 type 1 diabetes in patients
ages 8 and up with Stage 2 type 1 diabetes.
Shares were up 1 cent after hours st $8.25 before the stock was
halted due to pending news.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
November 17, 2022 18:24 ET (23:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Grafico Azioni Provention Bio (NASDAQ:PRVB)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Provention Bio (NASDAQ:PRVB)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Provention Bio Inc (NASDAQ): 0 articoli recenti
Più Provention Bio Inc Articoli Notizie